secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0000950142-22-003160
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx settles litigation, transfers aviptadil assets to Relief for up to $43M in milestones/royalties; Q3 net loss $9.1M
--------------------------------------------------------------------------------

- NRx transfers all ZYESAMI (aviptadil) assets to Relief Therapeutics; receives up to $13M in milestones + up to $30M royalties capped; litigation dismissed at closing within 30 days.
- Q3 2022 net loss $9.1M vs $37.0M in Q3 2021; R&D $4.1M, G&A $5.0M; cash $18.2M at Sep 30, 2022.
- Completed $10M unsecured debt financing on Nov 7, 2022, net proceeds to support NRX-101 development.
- NRx to initiate registrational Phase 3 trial of NRX-101 in bipolar depression with acute suicidality by year-end 2022; top-line data expected 3Q 2023.
- NRx agrees not to compete in aviptadil development; Relief must use commercially reasonable efforts to commercialize and continue Right to Try program for 2 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000095014222003160/0000950142-22-003160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000095014222003160/eh220304751_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950142-22-003160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer